Skip to content
ATLAS PREP HQ
Longevity

Testagen

Lys-Glu-Asp-Gly (KEDG) tetrapeptide bioregulator

Peptide bioregulator research focused on endocrine function and the pituitary-gonadal axis.

Preclinical Evidence

Route

Subcutaneous in the community educational protocol.

Common format

20 mg vial

Research focus

pituitary-gonadal signaling

Evidence level

Preclinical Evidence

Typical cycle

8–12 weeks

Longevity research motifLongevity

Testagen in 30 seconds

Atlas Fast Read

What it is

Lys-Glu-Asp-Gly (KEDG) tetrapeptide bioregulator

Why people care

Peptide bioregulator research focused on endocrine function and the pituitary-gonadal axis.

Human evidence

Preclinical Evidence — The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

Biggest misconception

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Bottom line

Testagen is scientifically interesting for pituitary-gonadal signaling, thyroid/endocrine models, but the current case is driven mainly by cell and animal data.

Overview

What is Testagen?

Testagen is lys-Glu-Asp-Gly (KEDG) tetrapeptide bioregulator. Peptide bioregulator research focused on endocrine function and the pituitary-gonadal axis.

Testagen is a short peptide from the Khavinson anterior-pituitary bioregulator program. Its evidence base is preclinical and focuses on endocrine and pituitary-gonadal signaling.

Mechanism

How it works

KEDG is proposed to act as a short gene-regulatory peptide affecting anterior-pituitary/endocrine pathways. Current mechanistic support comes from in vitro and animal work rather than human pharmacology.

Research areas

pituitary-gonadal signalingthyroid/endocrine modelsreproductive biologygene regulation

Evidence

What does the evidence actually say?

Preclinical Evidence

The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

No modern controlled human evidence establishes Testagen for testosterone, fertility, pituitary rejuvenation, or endocrine performance. Its evidence is predominantly preclinical.

Preclinical evidence

Cell and animal studies report gene-regulatory and pituitary/endocrine effects of the KEDG tetrapeptide. Independent human confirmation is lacking.

Knowledge gaps

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

community sources experimental reference: 100–300 mcg/day with titration. No human clinical dose is established.

Frequency

Once daily.

Timing

No established time-of-day requirement.

Route

Subcutaneous in the community educational protocol.

Cycle length

8–12 weeks

Reconstitution

Community reference: 2 mL bacteriostatic water per 20 mg vial = 10 mg/mL.

Storage

Community reference: lyophilized at -20 °C; reconstituted 2–8 °C; avoid freeze-thaw.

Monitoring

If studied for endocrine effects, LH, FSH, testosterone/estradiol and thyroid markers are more informative than generic wellness panels. No validated safety-monitoring schedule exists.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Human safety data are insufficient. Potential adverse effects include injection-site reactions, headache, fatigue, dizziness, nausea and unknown long-term effects on gene regulation, growth, metabolism or immune function.

Contraindications

No validated human contraindication profile exists. Avoid use outside research oversight in pregnancy/breastfeeding, active malignancy, significant organ disease or known hypersensitivity.

Interactions

Formal drug-interaction studies are absent or very limited. Interactions with anticancer, endocrine, metabolic and immunomodulatory therapies are unknown.

Stacks

Common stacks

No well-supported stack is highlighted for this peptide yet.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

Testagen is scientifically interesting for pituitary-gonadal signaling, thyroid/endocrine models, but the current case is driven mainly by cell and animal data. Atlas would treat claimed benefits as hypotheses—not established human outcomes—and would put human safety, product quality, and controlled trials ahead of protocol optimization.

More in Longevity

Longevity

Cortagen

Peptide bioregulator research focused on neuroregeneration, brain aging, and cognitive function.

Read guide

Longevity

Epitalon

Pineal-derived tetrapeptide research exploring telomerase activity, circadian biology, and healthy aging.

Read guide

Longevity

FOXO4-DRI

Experimental senolytic peptide research investigating selective removal of senescent cells.

Read guide